ROIV Stock Recent News
ROIV LATEST HEADLINES
Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first quarter financial results that fell short of expectations for both earnings and sales. For the three months ended June 30, 2023, the company reported a loss per share of $0.38, $0.10 lower than the Street estimate of a loss per share of $0.28.
With everyone being an expert these days, the concept of top analyst biotech picks might seem suspect at first glance. While we depend on Wall Street's spectrum of expert guidance to establish a frame of reference, they can get some calls embarrassingly wrong.
Growth stocks have returned to form this year. Roivant Sciences and Viking Therapeutics are two growth plays that should interest risk-tolerant investors.
The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry's research and development. Large biotech companies such as Johnson and Johnson (NYSE: JNJ ), Merck (NYSE: MRK ), and AbbVie (NYSE: ABBV ) offer investors steady and continual growth as well as decent dividends.
Shares of Roivant ROIV rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche RHHBY was close to buying ROIV's inflammatory bowel disease (IBD) candidate, RVT-3101, for more than $7 billion.
Roivant Sciences is in talks to sell an experimental drug that can treat debilitating stomach diseases in a deal that could be valued at more than $7 billion.
Acadia Pharmaceuticals Inc.'s stock ACAD, -0.23% surged 18% in premarket trading after the company expanded drug rights to a treatment for a rare neurological disorder.
Shares of Roivant Sciences Ltd. ROIV, +1.58% surged in the extended session Thursday following a report that Roche Holding ROG, +0.62% was close to buying an experimental drug from the biotech company.
Roivant Sciences Ltd is attracting interest from large pharmaceutical companies for its inflammatory bowel disease drug, Bloomberg News reported on Thursday, citing people familiar with the matter.
Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume.